Currently, humans are immersed in a pandemic caused by the emerging severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), which threatens public health …

The mainstream approach to antiviral drugs against COVID‐19 is to focus on key stages of
the SARS‐CoV‐2 life cycle. The vast majority of candidates under investigation are …

The rapid outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) in China followed by its spread around the world poses a serious global concern for …

Middle East respiratory syndrome coronavirus (MERS-CoV) is a new highly pathogenic
human coronaviruses that emerged in Jeddah and Saudi Arabia and has quickly spread to …

Structure-guided design was used to generate a series of noncovalent inhibitors with
nanomolar potency against the papain-like protease (PLpro) from the SARS coronavirus …

The papain-like protease (PLpro) domain from the deadly Middle East respiratory syndrome
coronavirus (MERS-CoV) was overexpressed and purified. MERS-CoV PLpro constructs …

The Middle East Respiratory Syndrome coronavirus (MERS-CoV) papain-like protease
(PLpro) blocking loop 2 (BL2) structure differs significantly from that of SARS-CoV PLpro …

We assessed various newly generated compounds that target the main protease (Mpro) of
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and various previously …

The SARS-CoV2 is a highly contagious pathogen that causes COVID-19 disease. It has
affected millions of people globally with an average lethality of~ 3%. There is an urgent need …

The unforeseen emergence of coronavirus disease 2019 (COVID-19), a severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) at the Wuhan province of China in …